Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Real-world experience of combined treatment with azacitidine and romidepsin in patients with peripheral T-cell lymphoma

15 Feb 2023

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Chronic Lymphocytic Leukemia Research
Share to Lymphoma Diagnosis and Treatment
Share to Peptidase Inhibition and Analysis

Source

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Identifiers

PMID: 36790924
DOI: 10.1182/bloodadvances.2022009445

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Real-world experience of combined treatment with azacitidine and romidepsin in patients with peripheral T-cell lymphomaPMID 36790924Read ↗

Combined oral 5-azacytidine and romidepsin are highly effective in patients with PTCL: a multicenter phase 2 study.Semantic proximity Read ↗

Romidepsin and Azacitidine Synergize in their Epigenetic Modulatory Effects to Induce Apoptosis in CTCLSemantic proximity Read ↗

Histone Deacetylase Inhibitors for Peripheral T-cell Lymphomas: From Biology to Real-World TherapySemantic proximity Read ↗

Phase I study of vorinostat in combination with standard <scp>CHOP</scp> in patients with newly diagnosed peripheral T‐cell lymphomaSemantic proximity Read ↗

Phase II trial of romidepsin as consolidation therapy after gemcitabine, dexamethasone, and cisplatin in elderly transplant-ineligible patients with relapsed/refractory peripheral T- cell lymphomaSemantic proximity Read ↗

A multi-centre phase 2 study of azacitidine in chronic myelomonocytic leukaemiaSemantic proximity Read ↗

A phase 1 trial of alisertib and romidepsin for relapsed/refractory aggressive B-cell and T-cell lymphomasSemantic proximity Read ↗

Induction of p53-mediated apoptosis by azacitidine in patient-derived xenograft follicular helper T-cell lymphoma modelSemantic proximity Read ↗

Azacitidine differentially affects CD4pos T-cell polarization in vitro and in vivo in high risk myelodysplastic syndromesSemantic proximity Read ↗

The Future of Combination Therapies for Peripheral T Cell Lymphoma (PTCL).Semantic proximity Read ↗

Targeting histone deacetylases in T-cell lymphomaSemantic proximity Read ↗

Induction of p53-mediated apoptosis by azacitidine in patient-derived xenograft follicular helper T-cell lymphoma model.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.